Cancer

Add us on Google

LucenceINSIGHT vs. GRAIL Galleri: MCED Cancer Tests Compared

How LucenceINSIGHT and GRAIL Galleri compare for multi-cancer early detection, including how each works, cancer coverage, panel choices, origin prediction, and shared limits.

Published

August 27, 2026

Last updated

October 20, 2026

Read time

11 min read

Medically reviewed by

Rhonda Collins, FNP-C

Share

Copy link

Summarize with AI

Multi-cancer early detection (MCED) blood tests look for signs of cancer from a single draw, across several cancer types at once. Mito offers two of them, and they take different design approaches. LucenceINSIGHT sequences circulating tumor DNA and cancer-associated viral DNA, then uses machine learning to predict where a signal came from. It is available as two fixed panel options and one customizable option. Galleri casts a wider net, looking for a single shared cancer signal detectable across many cancer types and predicting the likely signal origin. Neither is better in the abstract. Both are legitimate screening tools, and the right one depends on what you want the test to do. Both are screening tests, not diagnoses, and both are meant to add to, not replace, the cancer screening your doctor already recommends.

Not sure where to start? The Cancer Risk Profile quiz can help you think through your personal risk before you choose.

What does each test actually do?

LucenceINSIGHT is a next-generation-sequencing MCED test. From one blood draw it detects circulating tumor DNA (ctDNA) mutations and cancer-associated viral DNA, and a machine-learning model predicts the likely tissue or tumor of origin. The idea is signal to tissue of origin: find a cancer-associated signal, then point toward where to look. In a Lucence validation cohort, the test showed an overall sensitivity of 80.9% (233 of 288 cancer patients across multiple stages, retrospective) and a specificity of 99.0% (310 of 313 self-declared healthy donors), with tumor-localization accuracy of 87.7% overall (Lucence Health validation data). Those numbers are averages across a mixed group and do not apply evenly to every cancer or stage.

Galleri is an MCED test from GRAIL. Rather than reading tumor mutations gene by gene, it looks for a single shared cancer signal that can be present across many cancer types, detected from one blood draw, and it returns a predicted cancer signal origin to guide follow-up when a signal is found (Source: grail.com). The appeal is breadth: one signal type screened across a wide range of cancers in a single test.

GRAIL has published Galleri’s performance in several studies, and each figure belongs to its own study and population. In CCGA3, a case-control validation of 2,823 people with cancer and 1,254 without, test sensitivity was 51.5% and specificity was 99.5%. Sensitivity rose with stage, from 16.8% at stage I to 90.1% at stage IV ^[1]. In PATHFINDER 2, which screened 32,007 adults 50 and older with no suspicion of cancer, episode sensitivity was 39.3%, specificity was 99.64%, and 60.3% of positive results were confirmed as cancer ^[2]. Episode sensitivity is the share of cancers diagnosed within 12 months of a test that the test had flagged. It is not directly comparable with test sensitivity from a case-control study, because the two come from different populations with different mixes of cancer types and stages. The same caution applies to setting either study next to Lucence’s validation cohort. For what these numbers mean for an individual result, see how accurate Galleri is and what its results mean.

How do their panels differ in philosophy?

This is the clearest difference. LucenceINSIGHT offers fixed focused or broad panels plus a customizable option. Galleri is built to be broad.

LucenceINSIGHT comes in three panels through Mito:

• Core is a fixed panel that screens for signals associated with 6 cancers that together account for more than 50% of US cancer mortality: thyroid, breast, pancreatic, colorectal, lung, and liver (mortality coverage estimated from GLOBOCAN 2024).
• Me adds 1 to 3 more cancers chosen with your doctor from a curated list of 12, for 7 to 9 total, personalized to your family history and personal risk. Estimated mortality coverage is 53 to 76% depending on what you select.
• 12 offers fixed male and female panels covering 12 cancers, roughly 78% of US cancer mortality (GLOBOCAN 2024, conservative upper-limit estimate). You choose the panel matching your sex, but you do not choose individual cancers.

Galleri takes the opposite tack. Instead of a panel you tune, it screens for one shared signal across a wide range of cancer types in a single test, including cancers that have no routine screening at all (Source: grail.com). Breadth has real value because prediction is imperfect and many deadly cancers lack a standard screening path. Focus also has value, because risk, detectability, and the action you would take differ by cancer. There is no universally correct answer between the two.

Side-by-side comparison

LucenceINSIGHT figures are from Lucence Health validation data and reflect the study populations named above. Galleri figures are from the CCGA3 (Annals of Oncology, 2021) and PATHFINDER 2 (Nature Medicine, 2026) publications; other Galleri details reflect publicly available GRAIL information. Figures from different studies are not directly comparable. Confirm current test specifications before ordering.

What did the NHS-Galleri trial find?

NHS-Galleri is the only randomized controlled trial of Galleri. It enrolled 142,250 people aged 50 to 77 in England and compared standard NHS screening alone with standard screening plus three yearly Galleri tests. Its main goal was to reduce the number of stage III and stage IV cancers combined, and it did not meet that goal: there was no difference between the two groups ^[3]. Looked at on their own, stage IV cancers were less common in the test group, and more early-stage cancers were diagnosed. No study has yet shown that Galleri reduces cancer deaths.

The trial also reported how the test performed in its test group: 30.7% of people who had cancer got a positive result (episode sensitivity), 99.55% of people without cancer got a negative result, and 52.0% of people with a positive result were diagnosed with cancer ^[4]. These are conference results that GRAIL says will be submitted to a peer-reviewed journal.

How fast are results?

LucenceINSIGHT has a stated turnaround of about 25 working days from the lab (Lucence). Galleri returns results from a single blood draw as well, but we are not stating a specific turnaround here because it is not confirmed in our source materials. Check the current turnaround when you order either test.

Who does each test suit?

Both tests are aimed at adults who want to widen their cancer screening beyond the handful of cancers covered by standard guidelines, but their age guidance differs. Lucence positions LucenceINSIGHT for adults 40 and older, or younger adults with elevated risk from family history, lifestyle, or other factors. GRAIL recommends Galleri for adults with an elevated risk for cancer, such as those age 50 or older. If you are in your 40s, LucenceINSIGHT is the one that fits the published guidance. Either way, MCED testing is an addition to guideline-recommended screening, not a replacement.

LucenceINSIGHT may fit if you want a fixed focused panel, a fixed broader panel, or a panel you personalize with your doctor. Only Me allows cancer selection: it adds 1 to 3 cancers to the fixed Core set based on your family history and personal risk. Core has no cancer selection, and LucenceINSIGHT 12 only asks you to choose its fixed male or female panel.

Galleri may fit if you want the widest possible net in a single test and prefer not to choose which cancers to include, especially to reach cancers with no routine screening path. Some people value breadth precisely because it is hard to predict in advance where a cancer might arise.

Many people reasonably consider either. The Cancer Risk Profile quiz is a good first step to clarify your risk picture.

What limitations do both share?

These matter as much as the differences, and they apply to every MCED test:

• They screen, they do not diagnose. A cancer-associated signal is a reason for your doctor to order confirmatory workup, not a diagnosis on its own.
• They add to guideline screening, they do not replace it. Keep up with mammograms, colonoscopy, lung CT, and other recommended screening. MCED is designed to close gaps, not to substitute for proven tools. More than half of US cancer deaths involve cancers not covered by recommended screening (derived from GLOBOCAN 2024 and USPSTF-recommended cancers), which is the gap these tests try to narrow.
• A negative result does not mean cancer-free. Sensitivity varies by cancer type and stage, and being included on a panel does not mean a cancer is equally detectable. Early-stage cancers shed less signal and are harder to catch than later-stage disease. About 52.8% of cancers are still diagnosed at a late stage (Zeng H et al., Lancet 2021), which is part of why early detection matters and also why no single test catches everything.
• They do not assess inherited risk. Neither is a substitute for genetic counseling or germline testing.

Why choose either one through Mito?

The Mito-distinctive part is not that one test beats the other. It is that you can order either LucenceINSIGHT or Galleri through Mito and integrate the result with the rest of your bloodwork, so a cancer screen sits alongside your metabolic, cardiovascular, hormone, and other markers instead of living in a silo. You also get telehealth ordering, Mito Concierge for follow-up questions, and the option of a 1:1 consultation to talk through what a result means and what to do next.

Mito members pay Mito’s cost on tests. Membership is $9 per month or $99 per year, and any applicable lab order or draw fee is itemized before you pay. Non-members can order at the non-member price.

FAQs

Is Galleri or LucenceINSIGHT more accurate? There is no head-to-head study that lets us rank them, and accuracy is not a single number: it varies by cancer type and stage for both. LucenceINSIGHT reports an overall sensitivity of 80.9% and specificity of 99.0% in a Lucence validation cohort. Galleri showed a test sensitivity of 51.5% and specificity of 99.5% in GRAIL’s CCGA3 case-control study, and an episode sensitivity of 39.3%, specificity of 99.64%, and positive predictive value of 60.3% in the PATHFINDER 2 screening study. These figures come from different study designs and populations, so they cannot be lined up to rank the tests. Use each test’s own materials rather than comparing headline figures directly.

Can I take both? That is a conversation for your doctor. They serve overlapping goals, so most people choose one. Your clinician can help weigh focus versus breadth for your situation.

Do these replace my mammogram or colonoscopy? No. Both are adjuncts to guideline-recommended screening, not replacements. Keep your standard screenings on schedule.

What happens if a signal is found? A positive or cancer-associated result needs confirmatory workup ordered by a doctor. Both tests predict a likely origin: LucenceINSIGHT uses machine learning to predict the likely tissue or tumor of origin, and Galleri reports a predicted cancer signal origin. These predictions help direct follow-up, but neither result is a diagnosis.

Who should consider an MCED test at all? It depends on the test. Lucence positions LucenceINSIGHT for adults 40 and older, or younger adults with elevated risk, while GRAIL recommends Galleri for adults with an elevated risk for cancer, such as those age 50 or older. Either way, it is an addition to recommended screening. The Cancer Risk Profile quiz can help you think it through.

Related reading

• What Is a Multi-Cancer Early Detection (MCED) Test?
• How Accurate Is Galleri, and What Do Its Results Mean?
• How Often Should You Take the Galleri Test?
• Multi-Cancer Blood Test: Cost and How to Get One
• CA 125 Explained: What Your Cancer Antigen Test Results Mean

Medical disclaimer

This article is for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Multi-cancer early detection tests are prescription-only screening tests, not diagnostic tests, and they do not replace guideline-recommended cancer screening. A negative or low-risk result does not mean you are cancer-free, and a positive result requires confirmatory evaluation ordered by a physician. Talk with your doctor about whether MCED testing is appropriate for you, and verify current test specifications and pricing before ordering.

References

1. Klein EA et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021.
2. Nabavizadeh et al. Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study. Nature Medicine. 2026.
3. NHS-Galleri Trial: What the trial found
4. NHS-Galleri Trial: How accurate was the test?